Skip to main content
. 2023 Sep 25;13(19):3043. doi: 10.3390/diagnostics13193043

Figure 3.

Figure 3

Association between KRAS mutation status and survival in non-small cell lung cancer, (A). Overall Survival for KRAS G12C mutant tumors versus wild-type KRAS tumors [37,39,43,46,48,49,51]; (B). Disease-free survival for KRAS G12C mutant tumors versus wild-type KRAS tumors [46,49].